At 1 year , the primary outcome was reached in 23.3 % of patients allocated to abciximab vs. 28.0 % of patients allocated to placebo [ relative risk ( RR ) 0.80 , 95 % confidence interval ( CI ) 0.67-0 .95 , P = 0.012 ] .
